MARKET

EXAS

EXAS

EXACT Sci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

141.04
-12.89
-8.37%
Closed 19:55 01/26 EST
OPEN
153.85
PREV CLOSE
153.93
HIGH
154.56
LOW
140.00
VOLUME
2.63M
TURNOVER
--
52 WEEK HIGH
159.54
52 WEEK LOW
35.25
MARKET CAP
22.49B
P/E (TTM)
-64.2142
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25)
Benzinga · 21h ago
Apogee Enterprises, Inc. (NASDAQ:APOG) Passed Our Checks, And It's About To Pay A US$0.20 Dividend
Simply Wall St. · 2d ago
DJ Exact Sciences Price Target Raised to $170.00/Share From $160.00 by SVB Leerink
Dow Jones · 5d ago
DJ Exact Sciences Is Maintained at Outperform by SVB Leerink
Dow Jones · 5d ago
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 5d ago
Look for Shares of Exact Sciences to Potentially Pullback after Yesterday's 1.65% Rise
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $148.50 to a high of $152.80. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $151.50 on volume of 984,000 shares. Often times af...
Comtex SmarTrend(R) · 6d ago
Epigenomics falls after CMS decision; Guardant and Exact Sciences rise
Epigenomics (EPGNF) has lost 24.8% after the company announced that U.S. Centers for Medicare & Medicaid Services (“CMS”) issued a negative reimbursement decision related to the National Coverage Determination (“NCD”) of Epi
Seekingalpha · 6d ago
15 Best Undervalued Stocks to Buy Now
In this article, we present to you the 15 Best Undervalued Stocks to Buy Now. If you’re in a hurry, click to skip ahead and jump to the 5 Best Undervalued Stocks to Buy Now. Investing in the stock market could be difficult. We can classify investors based ...
Insider Monkey · 01/14 17:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXAS. Analyze the recent business situations of EXACT Sci through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EXAS stock price target is 154.79 with a high estimate of 170.00 and a low estimate of 140.00.
EPS
Institutional Holdings
Institutions: 792
Institutional Holdings: 152.62M
% Owned: 95.73%
Shares Outstanding: 159.42M
TypeInstitutionsShares
Increased
159
13.51M
New
154
1.18M
Decreased
174
9.32M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Conroy
Chief Financial Officer
Jeffrey Elliott
Senior Vice President/Chief Administrative Officer/General Counsel/Secretary
D. Scott Coward
Senior Vice President/Chief Scientific Officer
Graham Lidgard
Senior Vice President
Ana Hooker
Senior Vice President
Scott Johnson
Vice President - Operations/General Manager
Pat Setji
General Manager
Torsten Hoof
General Manager
Jake Orville
General Manager
Gisela Paulsen
Director
Shacey Petrovic
Independent Director
Thomas Carey
Independent Director
James Doyle
Independent Director
Pierre Jacquet
Independent Director
Daniel Levangie
Independent Director
Freda Lewis-Hall
Independent Director
Kathleen Sebelius
Independent Director
Michael Wyzga
Independent Director
Katherine Zanotti
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About EXAS
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Webull offers kinds of EXACT Sciences Corporation stock information, including NASDAQ:EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.